Self-assembled polypeptide and polypeptide hybrid vesicles: from synthesis to application. 2012

Uh-Joo Choe, and Victor Z Sun, and James-Kevin Y Tan, and Daniel T Kamei
Department of Bioengineering, University of California, Los Angeles, CA, 90095, USA.

The development of nanoscale drug delivery vehicles is an exciting field due to the ability of these vehicles to improve the pharmacokinetic and pharmacodynamic properties of existing therapeutics. These vehicles can improve drug effectiveness and safety by providing benefits such as increased blood circulation, targeted delivery, and controlled release. With regard to the building blocks, amphiphilic polypeptide and polypeptide hybrid (i.e., a macromolecule comprised of a polypeptide and another type of polymer) systems have been recently investigated for their abilities to self-assemble into vesicles. Advances in synthesis methodologies have allowed the development and characterization of many different amphiphilic polypeptide and polypeptide hybrid systems. In this review, we will discuss these vesicle-forming materials in terms of their synthesis, processing, and characterization. In addition, current efforts to use them for drug delivery purposes will be discussed.

UI MeSH Term Description Entries
D008853 Microscopy The use of instrumentation and techniques for visualizing material and details that cannot be seen by the unaided eye. It is usually done by enlarging images, transmitted by light or electron beams, with optical or magnetic lenses that magnify the entire image field. With scanning microscopy, images are generated by collecting output from the specimen in a point-by-point fashion, on a magnified scale, as it is scanned by a narrow beam of light or electrons, a laser, a conductive probe, or a topographical probe. Compound Microscopy,Hand-Held Microscopy,Light Microscopy,Optical Microscopy,Simple Microscopy,Hand Held Microscopy,Microscopy, Compound,Microscopy, Hand-Held,Microscopy, Light,Microscopy, Optical,Microscopy, Simple
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D004337 Drug Carriers Forms to which substances are incorporated to improve the delivery and the effectiveness of drugs. Drug carriers are used in drug-delivery systems such as the controlled-release technology to prolong in vivo drug actions, decrease drug metabolism, and reduce drug toxicity. Carriers are also used in designs to increase the effectiveness of drug delivery to the target sites of pharmacological actions. Liposomes, albumin microspheres, soluble synthetic polymers, DNA complexes, protein-drug conjugates, and carrier erythrocytes among others have been employed as biodegradable drug carriers. Drug Carrier
D004339 Drug Compounding The preparation, mixing, and assembly of a drug. (From Remington, The Science and Practice of Pharmacy, 19th ed, p1814). Drug Formulation,Drug Preparation,Drug Microencapsulation,Pharmaceutical Formulation,Compounding, Drug,Formulation, Drug,Formulation, Pharmaceutical,Microencapsulation, Drug,Preparation, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001672 Biocompatible Materials Synthetic or natural materials, other than DRUGS, that are used to replace or repair any body TISSUES or bodily function. Biomaterials,Bioartificial Materials,Hemocompatible Materials,Bioartificial Material,Biocompatible Material,Biomaterial,Hemocompatible Material,Material, Bioartificial,Material, Biocompatible,Material, Hemocompatible
D013501 Surface-Active Agents Agents that modify interfacial tension of water; usually substances that have one lipophilic and one hydrophilic group in the molecule; includes soaps, detergents, emulsifiers, dispersing and wetting agents, and several groups of antiseptics. Surface Active Agent,Surface-Active Agent,Surfactant,Surfactants,Tenside,Amphiphilic Agents,Surface Active Agents,Tensides,Active Agent, Surface,Active Agents, Surface,Agent, Surface Active,Agent, Surface-Active,Agents, Amphiphilic,Agents, Surface Active,Agents, Surface-Active
D015202 Protein Engineering Procedures by which protein structure and function are changed or created in vitro by altering existing or synthesizing new structural genes that direct the synthesis of proteins with sought-after properties. Such procedures may include the design of MOLECULAR MODELS of proteins using COMPUTER GRAPHICS or other molecular modeling techniques; site-specific mutagenesis (MUTAGENESIS, SITE-SPECIFIC) of existing genes; and DIRECTED MOLECULAR EVOLUTION techniques to create new genes. Genetic Engineering of Proteins,Genetic Engineering, Protein,Proteins, Genetic Engineering,Engineering, Protein,Engineering, Protein Genetic,Protein Genetic Engineering

Related Publications

Uh-Joo Choe, and Victor Z Sun, and James-Kevin Y Tan, and Daniel T Kamei
January 2011, Macromolecular bioscience,
Uh-Joo Choe, and Victor Z Sun, and James-Kevin Y Tan, and Daniel T Kamei
November 2007, Journal of the American Chemical Society,
Uh-Joo Choe, and Victor Z Sun, and James-Kevin Y Tan, and Daniel T Kamei
July 2010, Cold Spring Harbor perspectives in biology,
Uh-Joo Choe, and Victor Z Sun, and James-Kevin Y Tan, and Daniel T Kamei
March 2014, Journal of the American Chemical Society,
Uh-Joo Choe, and Victor Z Sun, and James-Kevin Y Tan, and Daniel T Kamei
June 2015, Colloids and surfaces. B, Biointerfaces,
Uh-Joo Choe, and Victor Z Sun, and James-Kevin Y Tan, and Daniel T Kamei
January 2010, Macromolecular rapid communications,
Uh-Joo Choe, and Victor Z Sun, and James-Kevin Y Tan, and Daniel T Kamei
May 2017, Nanoscale,
Uh-Joo Choe, and Victor Z Sun, and James-Kevin Y Tan, and Daniel T Kamei
December 2018, Acta crystallographica. Section C, Structural chemistry,
Uh-Joo Choe, and Victor Z Sun, and James-Kevin Y Tan, and Daniel T Kamei
January 2008, Acta biomaterialia,
Uh-Joo Choe, and Victor Z Sun, and James-Kevin Y Tan, and Daniel T Kamei
January 2022, Advances in colloid and interface science,
Copied contents to your clipboard!